Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/002—Protozoa antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/002—Protozoa antigens
  • A61K39/012—Coccidia antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/002—Protozoa antigens
  • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
  • C07K14/445—Plasmodium
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
  • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/53—DNA (RNA) vaccination
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
  • A61K2039/541—Mucosal route
  • A61K2039/542—Mucosal route oral/gastrointestinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
  • A61K2039/552—Veterinary vaccine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55583—Polysaccharides
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the .txt file contains a sequence listing entitled "2014-02-13 5658-00201...ST25.txt” created on February 13, 2014 and is 40,3 ki loby tes in size.
• the Sequence Listing contained in this .txt file is part of the specification and is hereby cotporated by reference herein in its entirety.
• Coccidiosis an infectious disease of poultry, swine, and cattle caused by apicomplexan protozoan parasites (Eimeria spp, and related parasites) presents problems worldwide. Coccidiosis is among the top ten infectious diseases of poultry in terms of its economic impact on the poultry industry with production losses estimated to be up to $2 billion annually. Other apicomplexan parasites also cause disease, including Plasmodium, Ct ptoispKjridi m and Toxoplasma, which are the causative agents of malaria, cryptosporidiosis and toxoplasmosis, respectively.
• Typical signs of coccidiosis include rapid loss of appetite, reduction in weight, diarrhea and acute mortality. Outbreaks in a flock occur upon exposure to high levels of pathogen and in roost cases, coccidiosis predisposes birds to secondary bacterial infections. Traditional methods of disease control include the administration of antibiotics and chemotherapeatie agents. However, with continuous usage, this Iras led to resistance issues. Antibiotic use also decreases social acceptance of poultry meat. Vaccination is a rational approach because of its ability to confer long-term protection, typically for the entire lifespan of commercial chickens.
• a vaccine vector comprising a first polynucleotide sequence encoding an Apicompkxan Rhomboid polypeptide and methods of using the same are provided herein.
• a vaccine vector comprising a first polynucleotide encoding an Apkomlexan Rhomboid polypeptide or an immunogenic fragment thereof and a second polypeptide sequence encoding an immunostimulatory polypeptide is disclosed.
• the Apkomplexan Rhomboid polypeptide and the immunostirnulatory polypeptide are suitably expressed on the surface of the vaccine vector.
• the Apicompkxan Rhomboid polypeptide may comprise SBQ ID NO: 1, SEQ I D NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SBQ ID NO; 37, SBQ ID NO: 38, an immunogenic fragment of at least one of SBQ ID NO: 1-4, 37-38 or combinations of SBQ ID NO: 1-4 and 37-38.
• the immunostimulatory polypeptide may be a CD 154 polypeptide capable of binding CD40 or an HMGBl polypeptide.
• the CD 154 polypeptides include fewer than 50 amino acids and comprise amino acids 140-149 of CD 154 or a homolog thereof.
• a vaccine vector comprising a first polynucleotide encoding an Apkomlexan Rhomboid polypeptide of SEQ I ' D NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SBQ ID NO: 37, SEQ ID NO: 38, an immunogenic fragment of at least one of SEQ ID NO: 1 -4 or 37-38 or combinations of SEQ ID NO: 1 -4 or 37-38.
• the Apicompkxan Rhomboid polypeptide may be expressed on the surface of the- vaccine vector.
• Vaccine vectors according to the present invention may be a virus, yeast, bacterium, or liposome vector.
• Pharmaceutical compositions may be comprised of the vaccine vectors described herein and a pharmaceutically acceptable carrier.
• the enhanced immune response may be an enhanced antibody response, an enhanced T ceil response or a combination thereof.
• a vaccine vector as - J - described herein is provided.
• the vaccine vector is capable of reducing the morbidity and mortality associated with subsequent infection with an apieomplexan parasite in. subjects administered the vaccine vector as compared to controls.
• Figure I is a schematic representation showing the homology of the MPP sequence among several Apieoropiexan parasites.
• the consensus MPP sequence is highly similar in amino acid sequences in the Apiconiplexa.ns. Positions that are not identical are indicated with an X in the consensus sequence which is shown on the top line of the figure and is SEQ ID NO: 38.
• the Toxoplasma gondii sequences (the first four lines be!ow the consensus) share .100% identity to the MPP sequence of SEQ ID NO: 2 from Eimeria maxima.
• the bottom two sequences are the homolog from Neospom eammm (SEQ ID NO: 3) and Eimeria tenetta (SEQ ID NO: 4), respectively.
• FIG. 2 is & schematic representation of the vaccine vector constructs described in the Examples.
• Figure 3 is a bar graph showing the body weight (grams) of the chickens eight days post-infection with Eimeria maxima after inoculation with the indicated vaccine vector expressing the indicated sequences. Significant differences (p ⁇ 0.05) between treatment groups are indicated by different letters.
• Figure 4 is a bar graph showing the body weight (grams) of the surviving chickens 29 days post-challenge infection with Eimeria maxima after inoculation with the indicated vaccine vector expressing the indicated sequences. Significant differences (p ⁇ 0.05) between treatment groups are indicated by actual p values and an asterisk (*).
• Figure 5 is a bar graph showing the percent mortality in the face of a virulent challenge infection with Eimeria maxima at eight days post-challenge infection with Eimeria maxima after inoculation with the indicated vaccine vector expressing the indicated sequences. Significant differences (p 0.05) are indicated with an asterisk (*).
• Species of Eimeria are highl immunogenic and are capable of stimulating robust host immune responses.
• the wide repertoire of antigens that are part of this eukaryote are highly specialized in function and are suitable targets for recombinant vaccine development Sporoxoites and mer zohes are the most motile stages of the parasite and are responsible for initiating and sustaining an active infection, invasion of these stages into intestinal epithelial cells is an essential process for the parasite to continue its life-cycle within host cells.
• a highly specialized set of organelles located at the anterior (apical) end of the parasite is involved in. transporting the numerous proteins required for the translocation of these motile stages from the intestinal lumen into the epithelial layer.
• This apical complex consists of a variety of secretory organelles including a large number of mkronemes that transport a milieu of proteins to the surface of motile apicompiexan zoites in support of the essential function, of motility.
• thrombospondin- related adhesive protein has been used as a successful recombinant antigen in Salmonella recombinant and Bacillus- vectored systems as a vaccine candidate. See U.S. Publication No, 261 1/01 1 1015. which is incorporated herein by reference in its entirety.
• Many microneme proteins have a similar mode of action in that they are released from the microneme complex, at the anterior end of the sporozoite as they approach a host ceil and act as a Sink between, the parasite and whatever substrate they are upon. The microneme protein is then translocated across the surface of the parasite posteriorly , thereby moving the parasite closer to the host cell.
• This gliding form of motility is ty pical of all apicompiexan parasites.
• the microneme protein When the microneme protein has been translocated to the posterior end of the parasite, it needs to be cleaved and released from the surface of the parasite in order to successfully complete the invasion process.
• This function is performed by a family of proteases that are const! tutively expressed within or on the parasite cell membrane. The cleavage process occurs intraceliularty and is an absolute requirement for propagating the infection.
• a novel approach to recombinant vaccine design involves targetin this protease and interfering with the cleavage/invasion process.
• the family of proteases that are involved in the cleavage process are called rhomboid proteases and are extremely we IS -described in Toxoplasma species with homolo ues in Eimeria and other Apicompiexa.
• Rhomboid proteases ROM and ROMS, MP?) are centrally implicated in the cleavage of mieroneme proteins and share good homology among different apicomplexan parasites.
• ROMS Predicted antigenic regions of MPP (ROMS) were aligned and checked for homology among six different Apicompiexa ( Figure 1 ). The seven sequences compared are as follows: Eimeria temlfo ROM4 (JN558353), Toxoplasma gondii ME49 ROMS (XP 002370238), Toxoplasma gondii ROMS (AAT84606), Toxoplasma gondii ROMS (AY587208), Toxoplasma gondii RM ROMS (AM055942), Toxoplasma gondii ( ⁇ 634626), and the MPP insert from Eimeria maxima of SBQ ID NO: 2.
• Suitable Apicomplexan parasites include, but are not limited, to: Eimeria species, including but not limited to Eimeria ienetta, Eimeria maxima, and Eimeria burnetii; Toxoplasma gondii; Neospora aninum; Cryptosporidium species; and Plasmodium species, including but not limited to Plasmodium falciparum, Plasmodium malaria ⁇ Plasmodium knowkm, and. Plasmodium vivax.
• Recombinant DNA technologies enable relatively easy manipulation of many yeast, bacterial and viral species. Some microorganisms are mildly pathogenic or non-pathogenic, but are capable of generating a robust immune response. These microorganisms make attractive vaccine vectors for eliciting an immune response to antigens recombinantly expressed in the vector. Vaccines vectored by microorganisms may mimic a natural infection, help produce .robust and long lasting mucosal immunity, and may be relatively inexpensive to produce and administer. In addition, such vectors can often carry more than one antige -and have potential to provide protection, against multiple infectious agents.
• a vaccine vector comprising a first polynucleotide sequence encoding an Apicomplexan Rhomboid polypeptide of SEQ ID NO; 1-4, 37-38, an immunogenic fragment thereof or combinations thereof is provided.
• the vaccine vector may include a first polynucleotide encoding an Apicomplexan Rhomboid polypeptide and a second polynucleotide encoding an immunostimulaiory polypeptide is provided.
• the Rhomboid polypeptide and the optional iuuu unostimulatory polypeptide are expressed oh the surface of the vaccine vector.
• the .Rhomboid polypeptide may comprise the full-length protein (SEQ I ' D NO: 39) or an immunogenic fragment such as those provided in SBQ ID NO: 1-4 and 37-38,
• the Rhomboid polypeptide may comprise, may consist essentially of or may consist of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ I D NO; 4 e SEQ I ' D NO: 37, SEQ I ' D NO: 38 or an immunogenic fragment of any of these SEQ ID NOs, Combinations of these fragments may also be used in a vaccine vector.
• a vaccine vector may included SEQ ID NO: 1 -4 or 37-38.
• a single vaccine vector may include multiple copies of a single fragment as well.
• the immunogenic fragment of a Rhomboid polypeptide may be a sequence that is at least 5, 6, 7, 8, 10, 12, 14, 16, 18 or 20 amino acids Song and has at least 85%, 90%, 92%, 9 %, 95%, 96%, 97%, 98 or 99% percent identity to the fragments of SEQ ID NO: 1 -4 or 37-38 provided herein.
• the vaccine vectors provided herein are believed to be reducing morbidity and mortality associated with Eimeria infection by inducing an antibody response thai is capable, of blocking invasion of the parasites into cells.
• B cells epitopes are often hydrophilic in nature and this information can be used to generate immunogenic fragments to the polypeptides of SEQ I ' D NO; 1 -4 and 37-38 provided herein.
• a liydrophilicsty plot of SEQ ID NO; 2 reveals three hydrophilic areas of the peptide and three potential B cell epitopes including amino acids 1- I I. 38-27 and 1.-43 of SEQ ID NO: 2, These amino acid fragments correspond to amino acids 7-16 of SEQ ID NO: 3 and 37 and amino acids 12-21 of SEQ ID NO: 4.
• amino acids corresponding to ⁇ 8-2 of SEQ ID NO: 2 are highly conserved across species and genera of Apicompiexan parasites. An immune response to such a highly conserved epitope may allow for cross species or even cross genera immunity from a single vaccine.
• a vaccine includes any composition comprising a polynucleotide encoding an antigenic polypeptide that is capable of eliciting an immune response to the polypeptide
• a vaccine vector is a composition that can be engineered to carry antigens or inimunostimulato.ry polypeptides and may also comprise a adjuvant or be administered with an adjuvant to further increase the immune response to the parasite and provide better protection from morbidity and mortality associated with a subsequent infection.
• vectors such as bacterial vectors, for vaccination and generation of immune responses against Eimeria or other apicompiexan parasites such as Plasmodium (the causative agent of malaria) * Toxoplasma and Cryptosporidium is disclosed.
• the immune responses after administration of the vaccine vector need not be fully protective, but may decrease the morbidity or percentage mortality ⁇ i.e, likelihood of mortality) associated with subsequent infection.
• Polynucleotides encoding Rhomboid polypeptide antigens of SEQ ID NO: 1 -4, 37-38 or fragments thereof and other antigens from any number of pathogenic organisms may be inserted into the vector and expressed in the vector.
• the expression of these polynucleotides by the vecior will allow generation of antigenic polypeptides following immunization of the subject
• the polynucleotides may be inserted into the chromosome of the vector or encoded on piasmids or other extrachromosomai DNA.
• Those of skill in the art will appreciate that numerous methodologies exist for obtaining expression of polynucleotides in vectors such as Salmonella or Bacillus.
• the poly nucleotides may be operahJy connected to a promoter (e.g., a constitutive promoter, an inducible promoter, etc) by methods known to those of skill in the art.
• a promoter e.g., a constitutive promoter, an inducible promoter, etc
• polynucleotides encoding the Rhomboid antigens are inserted into a vector, e.g., a bacterial vector, such that the polynucleotide is expressed.
• the polynucleotides encoding the Rhomboid antigens may be inserted in frame in a polynucleotide encoding a transmembrane protein.
• the polynucleotide encoding the Rhomboid antigen is inserted into the vector polynucleotide sequence to allow expression of the Rhomboid antigen on the surface of the vector.
• the polynucleotide encoding Rhomboid antigen may be inserted in .frame into the vector polynucleotide in.
• the first polynucleotide encoding the Rhomboid polypeptide may be inserted into loop 9 of the lamB gene of Sah e a,
• the first: polynucleotide is inserted into or at a surface exposed end of a protein tha is attached to the ceil wall, but is not a transmembrane protein.
• the protein may be a secreted protein that is anchored or attached to the cell wail via a protein or lipid anchor, in the Examples, the MP? (SEQ ID ' NO: 2) polypeptide is inserted at the 3* end of the fibronectin binding protein (FbpB) af .Bacillus subtilb.
• the first polynucleotide encoding the Rhomboid antigen ma be inserted into a polynucleotide encoding a secreted polypeptide.
• polynucleotide encoding the Rhomboid antigen could be inserted in a wide variety of vector polynucleotides to provide expression and presentation of the Rhomboid antigen to the immune ceils of a subject treated with the vaccine.
• the polynucleotide encoding the Rhomboid antigen ma he included in a single cop or more than one copy. The multiple copies may be inserted in a single location or more than one location.
• multiple epitopes such as combinations of the Rhomboid antigens provided herein as SEQ ID NO: 1-4 and 37-38 or combinations of this epitope with other apieomplexan epitopes such as TRAP or epitopes from other pathogens may be inserted into the vector a the same or more than one location.
• the first polynucleotide encodes a portion of the Rhomboid polypeptide, the entire Rhomboid polypeptide or more than one epitope from the Rhomboid polypeptide.
• the combination of epitopes from more than one polypeptide from a single parasite or pathogen or the combination of epitopes from related pathogens is specifically contemplated.
• the polynucleotide may be inserted into the vector and may be inserted as a fusion protein containing mor than a single epitope.
• SEQ ID NOs: 2 and 15 (MPP- H GB1 ) or SEQ ID NOs: 2, 40 and 15 (MPP-TRAP-H GBI ) were incorporated Into a Bacillus vector.
• the portion of the Rhomboid polypeptide inserted into the vector is an. antigenic fragment.
• An antigenic fragment is a peptide or poly peptide capable of eliciting a cellular or humoral immune response or capable of reducing the morbidity or mortality associated with subsequent infection with the parasite.
• An antigenic polypeptide or epitope includes any polypeptide that is immunogenic.
• the antigenic polypeptides include, but. are not limited to, antigens that are pathogen-related, allergen-related, tumor-related or disease-related.
• Pathogens include viral, parasitic, fungal and bacterial pathogens as well as protein pathogens such as the prions.
• the antigenic polypeptides may b fall-length proteins or portions thereof. U is well, established, that immune system recognition of many proteins is based on a. relatively small number of amino acids, often referred to as the epitope. Epitopes may he only 4-8 amino acids long.
• the antigenic polypeptides described herein may be full-length proteins, four amino acid long epitopes or any portion between these extremes.
• the antigenic polypeptide may include more than one epitope from a single pathogen or protein.
• the antigenic polypeptides may have at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% percent identity to the SEQ ID NOs provided herein.
• an antigenic fragment of the Rhomboid antigen or polypeptide may be four, five* six, seven, eight, nine, 10 or more amino acids, 15 or more amino acids or 20 or more amino acids of the full-length protei sequence.
• the epitopes in the vaccine vector may be related and homologous to allow targeting of multiple related pathogens with a single vaccine vector. It is envisioned that several epitopes or antigens from the same or different pathogens or diseases may be administered in combination in a single vaccine vector to generate an enhanced immune response against multiple antigens.
• Recombinant vaccine vectors may encode antigens from multiple pathogenic microorganisms, viruses or tumor associated antigens. Administration of vaccine vectors capable of expressing multiple antigens has the advantage of inducing immunity against two or more diseases at the same time, providing broader protection against multiple strains of a single pathogen or a more robust immune response against a single pathogen.
• the MPP antigen (SEQ ID NO; 2) was co-expressed in several of the vectors with a second antigenic polypeptide.
• a high molecular mass, asexual stage antigen from Eimetia maxima (EmTFP250) was demonstrated to be a target for maternal antibodies produced by breeding hens infected with this protozoan parasite.
• Analysis of the amino acid sequence of the antigen revealed a novel member of the TRAP (thrombospondin-related anonymous protein) family, containing 16 thrombospondin type-! repeats and 31 epidermal growth factor-like calcium binding domains. See U.S. Patent Publication. No. 201 1/0111015.
• EmTFP250 or TRAP also contains two low complex, hydrophi!ic regions rich in glutamic acid and glycine residues, and a transmembrane domain/cytosolic tail associated with parasite gliding motility that is ighly conserved within apicomplexan microncme proteins.
• SEQ ID NO: 1 -3 and 1 1 of U.S. Patent Publication Mo. 20.1 1/01 1 1015 which are reproduced herein as SEQ ID NO: 5-8.
• SEQ ID NO: 40 was used in the Examples provided herein and is referred to as a TRAP antigen as well SEQ ID NO: 40 and SEQ ' ID NO: 6 van 1 by a single amino acid, A proline at position 6 of SEQ ID NO; 6 is changed to an arginine at the same position 6 of SEQ ID NO: 40. This change was made to make the epitope more- flexible and hydr philic with the goal of making it a better antigen. Those of skill in the art may make other single amino acids changes to improve antigenicity within the scope of this Invention.
• a vector may induce protective immunity against multiple apicomplexan parasites and administration of a vaccine vector comprising two distinct antigenic polypeptides may induce a more robust immune response.
• the antigenic polypeptides from other pathogens may be used in the vaccine vectors to enhance the .immune response against more than one pathogen by a single vaccine. It would be advantageous to administer a single vaccine directed against multiple pathogens.
• the second antigenic polypeptide may be an Influenza polypeptide, suitably it is an Influenza HSN 1 polypeptide or a polypeptide associated with multiple strains of the Influenza virus such as a polypeptide of the Influenza M2 protein.
• the eciodomain of the Influenza A virus M2 protein, known as M2e protrudes from the surface of the virus.
• the 2e portion of die 2 protein contains about 24 amino acids.
• the M2e polypeptide varies little from one isolate to the next within Influenza. In fact, only a few naturally occurring mutations in M2e have been isolated fro infected humans since the 1918 flu epidemic, in addition, influenza viruses isolated from avian and swine hosts have different, yet still conserved, M2e sequences.
• Suitable epitopes for inclusion in an Influenza A vaccine vector include, but are not Hmtted to, polypeptides of the hemagglutinin (HA) or the nuclear protein NP) of Influenza A.
• HA hemagglutinin
• NP nuclear protein NP
• the peptides of SEQ ID NO: 1 1 , SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14 may be included in a vaccine vector.
• any of these sequences may be used in combination with, any other epitope including epitopes derived from other pathogens or antigens.
• Immunostimulatory molecules included as part of the vaccine vector could potentially activate part of th immune system critical to long-lasting protection or provide an adju vant effect.
• S.nimunostimuiatory poiypepeticles may be polypeptides capable of stimulating a naive or adaptive immune response.
• the imm nostimiiiatory polypeptides are not natively associated with the vaccine vector and are polypeptides .natively associated with a vertebrate immune system., such as that of the subject to which th vaccine will be administered.
• immunostimulatory polypeptides Two immunostimulatory polypeptides are described herein, namely CD 1 54 and High Mobility Group Box 1 (HMGBI ) polypeptides, but one of skill in the a will appreciate that other immunostimulatory polypeptides could be used or alternatively could be used in combination wit those described herein.
• HMGBI High Mobility Group Box 1
• polynucleotides encoding polypeptides involved in triggering the immune system may also be included in a vaccine vector.
• the polynucleotides may encode immune .system molecules known for their stimulatory effects, such, as an imerleukin, Tumor " Necrosis Factor, interferon, complement, or another polynucleotide involved in immune-regulation.
• the vaccine may also include polynucleotides encoding peptides known to stimulate an immune response, such a the CD 1.54 or HMGB I polypeptide described herein.
• HMGBI High Mobility Group Box- 1
• the HMGBI (High Mobility Group Box- 1) protein was first identified as a DNA-binding protein critical for DNA structure and stability. It is a ubiquitously expressed nuclear protein that binds DNA with no sequence specificity. The protein is highl conserved and found in plants to mammals. The zebrafish. chicken and human HMGBI amino acid sequences are provided in SEQ ID NO: 23, SEQ ID NO; 15 and SEQ ID NO; 22, respectively. The sequence throughout mammals is highly conserved with 98% amino acid identity and the amino acid changes are conservative.
• HMGBI protein from one species can likely substitute for that from another species functionally.
• the full-length HMGBI protein or a portion thereof may be used as the HMGBI polypeptide in the vaccine vectors described, herein, HMGB I has two DNA binding regions termed A box as shown in SEQ ID NO: 16 and 17 and B box as shown in SEQ ID NO: 18 and 19. See Andersson and Traeey, Annu. Rev. Immunol. 2011 , 29: 139- 162, which is incorporated herein by reference in its entirety.
• HMGB I is a mediator of inflammation and. serves as a signal of nuclear damage, such as from .necrotic cells.
• HMGBI can also be actively secreted by cells of the monocyte macrophage l ineage in a process requ iring acetylation of the protein, translocation across the nucleus and secretion.
• Extracellular HMGBI acts as a potent mediator of inflammation by signaling via the Receptor for Advanced Glycated End-products (RAGE) and via members of the Toil-like Receptor lamily (TLR), in particular TLR4.
• RAGE Receptor for Advanced Glycated End-products
• TLR Toil-like Receptor lamily
• the RAGE binding activity has been identified and requires the polypeptide of SEQ ID NO; 20.
• TLR4 binding requires the cysteine at position .106 of SEQ ID NO: 15, which is found in the B box region of HMOB ! ,
• BMGB l The inflammatory activities of BMGB l do not require the full-length protein and functional fragments have been identified.
• the B box has been shown to be sufficient to mediate the pro-inflammatory effects of HMGB J. and thus SEQ ID NO: 18 and 19 are HMGB1 polypeptides or functional fragments thereof within the context of the present invention.
• SEQ ID NO: 18 and 19 are HMGB1 polypeptides or functional fragments thereof within the context of the present invention.
• the RAGE binding site and the pro-inflammatory cytokine activity have been mapped to SEQ i.D NO: 20 and SEQ ID NO; 21 , respectively.
• these polypeptides are functional fragments of H GSi polypeptides in the context of the present invention.
• the HMGB I polypeptide includes the RAGE binding domain at amino acids 150-183 of SEQ IB NO: 15 (SEQ ID NO: 20 or a homoiog thereof) and the pro-inflammatory cytokine activity domain between amino acids 89-109 of SEQ ID NO: 15 (SEQ ID NO; 2 ! or a homoiog thereof).
• HMG 1 polypeptides and functional fragments or homologs thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 97% identical, at least 96% identical, at least 95% identical, at least 90% identical, at least 85% identical or at least 80% identical to the HMGB I polypeptides of SEQ ID Os: 15 or 16-23.
• a vaccine vector may include a CD 1 54 polypeptide that i capable of binding CD40 in the subject and stimulating the subject to respond to the vector and its associated antigen.
• DCs dendritic cells
• AFC antigen, presenting cell
• T cells Upon activation by DCs, T cells expand, differentiate into effector cells, leave the secondary immune organs, and enter peripheral tissues.
• Activated cytotoxic X cells are able to destroy vims-infected ceils, tumor cells or even APCs infected with intracellular parasites (e.g.. Salmonella) and have been shown to be critical in the protection against viral infection.
• CD40 is a member of the TNF-recepto.r family of molecules and is expressed on a variety of cell types, including professional antigen-presenting cells (AFCs), such as DCs and B ce ls, interaction, of CD40 with its Ifgand CD 154 is extremely important and stimulatory for both humoral and cellular immunity.
• AFCs professional antigen-presenting cells
• CD40-bindmg region, of CD! 54 may be expressed on the surface of a vector, such as a Salmonella or Bacillus vector, and. results in an enhanced immune response against a co-presented peptide sequence as shown in the Examples provided herein and in U..S. Patent Publication No. 201 1/0027309, which is incorporated herein by reference in its entirety.
• a CD S 54 polypeptide may be a portion, of CD 154 full-length protein or the entire CD 154 protein.
• the CD 154 polypeptide is capabie of binding CD40.
• a CD 1 54 polynucleotide encoding a CD 154 polypeptide that is capable of enhancing the immune response to the antigen may be included in the vaccine.
• the CD 1 ' 54 polypeptide is fewer than 50 amino acids long, more suitably fewer than 40, fewer than 30 or fewer than 20 amino acids in length.
• the polypeptide may be between 10 and 15 amino acids, between 10 and 20 amino acids or between 1 and 25 amino acids in length.
• the CD 1 4 sequence and CD40 binding region are not highly conserved among the various species.
• the CD! 54 sequences of chicken and human are provided in. SEQ ID NO: 24 and SEQ ID NO: 25, respectively,
• CD40 binding regions of CD S.54 have been determined for a number of species, including human, chicken, duck, mouse and cattle and are shown in SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ I NO: 30, respectively. Although there is variability in the sequences in the CD40 binding region between species, the human CD.1 S4 polypeptide wa able to enhance the immune response in chickens. Therefore, one may practice the invention using species specific CD 154 polypeptides or a heterologous CD 154 polypeptide.
• CD 154 polypeptides of SEQ ID NO: 24-30 may be included in a vaccine vector or a polypeptide at least 99, 98, 97, 96, 95, 93, 90 or 85% identical to the sequences of SEQ ID NO: 24-30 may he included in a vaccine vector.
• the polypeptide from CD 1 54 stimulates an immune response at least in part, by binding to its receptor, CD40.
• a polypeptide homologous to the CD S 54 polypeptide which is expressed on immune cells of the subject and which is capabie of bindin to the CD40 receptor on macrophages and other antigen presenting cells. Binding of this ligand-receptor complex stimulates macrophage (and .macrophage lineage cells such as dendritic cells) to enhance phagocytosis and antigen presentation while increasing cytokine secretions known to activate other local immune cells (such as B-lymphocytes), As such, molecules associated with the CD 154 peptide are preferentially targeted for immune response and expanded antibody production.
• the antigenic polypeptides and the immunosttmulatory polypeptides are delivered via a vaccine vector.
• the vaccine vectors may be bacterial, yeast, viral or liposome-based vectors.
• Potential vaccine vectors include, hut are not limited to,. Bacillus (Bacillus suhii!is), Salmonella ⁇ Salmonella enteritkiis), Shigella, Escherichia. (E. colt), Yersinia, Bodanefkf, Lacfococciis, Lactobacillus , Streptococcus, Vibrio (Vibrio cholerae). Listeria, yeas!
• liver bacteriaL yeast or viral vaccine vectors may still pose risks to immunocompromised individuals and require additional regulatory scrutiny.
• use of vectors that are killed or inactivated or qualify as Generally Recognized As Safe (GRAS) organisms by the Food and Drug Administration (FDA) is desirable.
• the problem is generating a robust immune response using such, vectors.
• Methods of inactivating or killing bacterial, yeast or viral vaccine vectors are known to those of skill in the art and include, but are not limited to methods such as formalin mactivation, antibiotic- based inactivation, heai treatment and ethanol treatment.
• an immunosiimulatory polypeptide such as BMGB1 (high mobility group box I ) polypeptide on the surface of the vaccine vector.
• BMGB1 high mobility group box I
• the Examples demonstrate that this vector can be inactivated such that it cannot replicate and still elicit a robust immune response after administration.
• the vaccine vectors may be wild-type bacteria, yeasts or viruses that are not pathogenic.
• the vectors may be attenuated such that the vector has limited ability to replicate in the host or is not capable of growing without supplemented media for more than a .few generations. Those of skill in the art will appreciate that there are a variety of ways to attenuate vectors and means of doing so,
• At least a portion of the antigenic polypeptide and at least a portion of the immunostimulatory polypeptide are present or expressed on the surface of the vaccine vector.
• Present on the suriace of the vaccine vector includes polypeptides that are comprised, within an external loop of a transmembrane protein, interacting with, e.g., covalentiy or chemically cross-linked to, a transmembrane protein, a membrane lipid or membrane anchored carbohydrate or polypeptide.
• a polypeptide can be comprised within a transmembrane protein by bas ing the amino acids comprising the polypeptide linked, via a peptide bond to the N-terminus, C-termhtus or anywhere within the transmembrane protein (i.e.
• the polypeptides may be inserted between two amino acids of the transmembrane protein or in place of one or more amino adds of the transmembrane protein (i.e. deletion-insertion)).
• the polypeptides may be inserted into an external loop of a transmembrane protein.
• Suitable transmembrane proteins are sriA, cotB and lamB, but those of skill in the art will appreciate many suitable transmembrane proteins are available.
• Polypeptides may be linked to a membrane or cell wall anchored protein or lipid such that the antigenic polypeptide and the immunostirmilatory polypeptide are expressed on the surface of the vaccine vector.
• polynucleotides encoding the antigenic or immunosiimulatory polypeptides may be inserted into the chromosome of the vector or maintained extraehromosoma!ly ⁇ e.g., on a plasmid, BAC or YAC).
• a plasmid BAC or YAC
• polynucleotide encoding the imraunositimulatory polypeptide capable of enhancing the immune response to the antigenic polypeptide may also encode the antigenic polypeptide.
• the polynucleotide encoding the antigenic polypeptide may be linked to the polynucleotide encoding the immunostimulatory polypeptide, such that in the vector, the two polypeptides are portions of the same polypeptide, suc as in a fusion protein.
• a polynucleotide encoding the antigenic polypeptide also encodes the immunostimulatory polypeptide.
• the two polynucleotides encoding the polypeptides are bot inserted in frame in loop 9 of the lamB gene of Salmonella enteriikUs or anothe vaccine vector.
• bacterial polynucleotides encoding other transmembrane proteins and other loops of the lamB gene ma also be used.
• the polynucleotide encoding the antigenic polypeptide and/or the immunostimulatory polypeptide may be inserted into a secreted polypeptide that is displayed or presented on the surface of the vaccine vector through association wit a. protein, lipid or carbohydrate on the surface of the vaccine vector.
• a. protein, lipid or carbohydrate on the surface of the vaccine vector.
• the polynucleotide encoding the antigenic polypeptide and/or the i mmunostimulatory polypeptide could be inserted in a wide variety of vaccine vector polynucleotides to provide expression and presentation of the antigenic polypeptide and or the iniraunosiimuSatory polypeptide to the immune cells of a subject treated with the vaccine vector by expression on the surface of the vaccine vector.
• the coding region of the Apicomplexan Rhomboid . polypeptide and the immunostimulatory polypeptide can be fused to the C-terminus of the Staphylococcus aureus fibroneetia binding protein containing a sorting motif for sortase from Listeria. This allows the secreted proteins to be anchored on the cell wall of gram positive bacteria such as Bacillus. See Nguyen and ' Schumann, J Bioteehnol (2006) 122: 473-482, which is incorporated herein by reference in its entirety. This system was used in the Examples to allow expression of the Rhomboid polypeptide linked to HMGBl on the surface of Bacillus. Other similar methods may also be used,
• the polypeptides may be eovaSerrtly or chemically linked to proteins, lipids or carbohydrates to the memb ane, cell wall, or capsid if a viral vector is being used through methods available to persons of skill in the art.
• di-sulfide bonds or biotin - avidin cross-linking could be used to present the antigenic and tmraimostimulatory polypeptides on the surface of a vaccine vector.
• the antigenic polypeptide and the immunostimulatory polypeptide are part of a fusion protein.
• the two polypeptides may be directl linked via a peptide bond or may be separated by a linker, spacer, or a section of a third protein into which they are inserted in frame.
• an amino acid spacer was used between the polypeptides.
• a spacer may be between 2 and 20 amino acids, suitably between 4 and 10 amino acids, suitably between 6 and 8 amino acids.
• the amino acids in the spacer have a small side chain and are not charged, such a glycine, alanine or serine.
• a spacer including two glycine residues, two serine residues and arginine and two more serine residues was used. Those of skill in the art wi ll appreciate other spacers could be used.
• the vaccine vectors have the antigenic polypeptides ( .PP and/or TRAP polypeptides) and the immunostimulatory polypeptide (either CD 154 or BMGB1 or both) encoded on the same polynucleotide and in frame with each other, i alternative embodiments, the inrmunostimukitory polypeptide and the antigenic poiypeptide may be encoded by distinct polynucleotides.
• TRAP polypeptides the antigenic polypeptides
• the immunostimulatory polypeptide either CD 154 or BMGB1 or both
• the inrmunostimukitory polypeptide and the antigenic poiypeptide may be encoded by distinct polynucleotides.
• compositions comprising the vaccine vector and a pharmaceutically acceptable carrier are also provided.
• a pharmaceutically acceptable carrier is any carrier suitable for in vivo administration.
• the pharmaceutically acceptable carrier is acceptable for oral, nasal or mucosal delivery.
• the pharmaceutically acceptable carrier may include water, buffered solutions, glucose solutions or bacterial culture fluids. Additional components of the compositions may suitably include excipients such as stabilizers, preservatives, diluents, emulsifiers and lubricants.
• Examples of pharmaceutically acceptable carriers or diluents include stabilizers such as carbohydrates (e.g., sorbitol, mannttol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein-containing agents such as bovine serum or skimmed milk and buffers (e.g., phosphate buffer).
• stabilizers such as carbohydrates (e.g., sorbitol, mannttol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein-containing agents such as bovine serum or skimmed milk and buffers (e.g., phosphate buffer).
• the composition is suitable for freeze-drying or spray-drying.
• the vaccine vector in the compositions may not be capable of replication, suitably the vaccine vector is inactivated or killed prior to addition to the composition.
• the vaccine vector may contain a first polynucleotide encoding an Aplicomplexan Rhomboid polypeptide and a second polynucleotide encoding an immunostimulatory -polypeptide.
• the immunostirauiatory polypeptide is suitably a polypeptide natively associated with a vertebrate immune system and involved in stimulating an immune response.
• the immunostimulatory polypeptide may stimulate the native or adaptive immune response of the subject.
• a H CiB l polypeptide or a CD S 54 polypeptide as described more fully above may be used as the immunostimulatory polypeptide.
• the vaccine vector comprising an Apicomplexan Rhomboid polypeptide and an immanostimuiatory polypeptide is administered to a subject in an amount effective to enhance or effect an immune response of the subject to the vaccine vector and in particular to the antigenic Rhomboid polypeptide and suitably to the apicomplexan parasite.
• the enhanced immune response may include the antibody or T ceil, response, Suitably the immune response is a. protective immune response, but the immune response may not be fully protective, but ma be capable of reducing the morbidity or mortalit associated with infection.
• the immunostimulatory polypeptides may ⁇ be used to enhance the immune response in the subject to any foreign antigen or antigenic polypeptide present in the vaccine vector in addition to the Rhomboid polypeptide.
• the immunostimulatory polypeptide could be used to enhance the immune .response to more than one antigenic polypeptide present in a vaccine vector. Enhancing an immune response includes, but. is no limited to, inducing a therapeutic or prophylactic effect that is mediated by the immune system of the subject.
• enhancing an immune- response may include, but is not limited to, enhanced production of antibodies, enhanced class switching of antibody heavy chains, maturation of antigen presenting ceils, stimulation of helper T cells, stimulation of cytoly tic T cells or induction of T and B cell memory.
• the vaccine vector contains a polynucleotide encoding a polypeptide including amino acids 150- 183 and 89- 109 of the HMGB I polypeptide (SEQ I ' D NO: 15) or a homolog thereof.
• a 190 amino acid polypeptide of HMGBI was used.
• the -polynucleotide encodes a HMGB I. polypeptide from the same species as the subject.
• Heterologous combinations of HMGBI polypeptides and subjects e.g. a human HMGB I polypeptide for use in a chicken vaccine
• the HMGBI polypeptide may be used to enhance the immune response to more than one antigenic polypeptide present, in a vaccine vector.
• the polypeptide from HMGBI stimulates an immune response at least in pari by activating dendritic cells and macrophages and thus stimulating production of cytokines such as lL- 1 , lL-6, IFN-y and TNF-a, in the Examples, a polypeptide of HMGBI was expressed on the surface of the vaccine vector.
• the vaccine vector may suitably contain a CD 154 polypeptide capable of binding to CD40 and activating CD40.
• the vaccine comprising the polynucleotide encoding a CD 154 polypeptide capable of binding to CD40 is administered to a subject in an. amount effective to enhance or affect the immune response of the subject to the vaccine.
• the vaccine contains a polynucleotide encoding a polypeptide including amino acids 140- 149 of the human GDI 54 polypeptide (SEQ ID NO: 25) or a homolog thereof.
• a homologue of amino acid 1.40-1.4 derived from one species may be used to stimulate an immune response in a distinct species.
• the polynucleotide encodes a CD 1.54 polypeptide from the same species as the subject
• a polynucleotide encoding the polypeptide of SEQ .ID NO: 26 is used in human subjects
• a polynucleotide encoding the polypeptide of SEQ ID NO: 27 is used in chickens
• a polynucleotide encoding the polypeptide of SEQ I ' D NO: 28 is used in ducks
• a polynucleotide encoding the polypeptide of SEQ ID NO: 29 is used in mice
• a polynucleotide encoding the polypeptide of SEQ ID NO: 30 is used in cows.
• the methods comprise administering to a subject an effective amount of a vaccine vector comprising a first polynucleotide sequence encoding an Apicomplexan Rhomboid polypeptide.
• the vaccine vector may also include a second polynucleotide encoding an immunostimulatory polypeptide in an effective amoun
• the Rhomboid polypeptides may include SEQ ID NO: 1 -4, 37, 38 or combinations or fragments thereof.
• the insertion of the Rhomboid polypeptides into the vector may be accomplished in. a variety of ways know to those of skill in the art, including but not limited to the scarless site-directed mutation system described in BMC Biotechnol.
• the vector may also be engineered to express the Rhomboid polypeptides in conjunction with other antigenic polypeptides from apicomplexan parasites such as TRAP or from other pathogens including viruses such as Influenza M2e or bacteria such as Salmonella or E. coli.
• a polypeptide of CD 154 capable of binding CD40 or HMGB.I may be expressed by the vector to enhance the immune response of the subject to the Rhomboid polypeptide,
• compositions containing antigenic polypeptides may also be used to decrease the morbidity associated with subsequent infection by an apicomplexan parasite,
• the compositions may prevent the parasite from causing disease or may limit or reduce any associated morbidit in a subject to which the compositions or vaccine vectors described herein were administered.
• the compositions and vaccine vectors described herein may reduce the severity of subsequent disease by decreasing the length of disease, weight loss, severity of symptoms of the disease, decreasing the morbidity or mortality associated with the disease or reducing the likelihood of contracting the disease.
• the compositions may also reduce the spread of the parasite by inhibiting transmission.
• the morbidity or mortality associated with the disease after administration of the vaccine vectors described herein may be reduced by 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even 100% as compared to similar subjects not provided the vaccine vector.
• compositions may be administered by a variety of means including, but not limited to, intranasai!y, mueosal!y, by spraying.
• intradermal ! parenieraHy, subeutaneousry,, intraperitoneiiy, intravenously, intraerannially, orally, by aerosol or intramuscularly.
• Eye-drop administration, oral, gavage or addition to drinking water or food is additionally suitable.
• the compositions may be administered in v .
• Suitable subjects may include, but are not limited to, vertebrates, suitably mammals, suitably a human, and birds, suitably -poultry such as chickens or turkeys. Other animals such as cows, eats, dogs or pigs may also be used.
• the subject is on- human and may be an agricultural animal.
• the useful dosage of the vaccine to be administered will vary depending on the age, weight and species of the subject, the mode and route of administration and the type of pathogen against which an immune response is sought
• the composition may be administered in any dose sufficient to evoke an immune response, it is envisioned, that doses ranging from ⁇ 0 3 to K )i0 vector copies (i.e. colony forming units or plaque forming units), from I0 4 to S O 9 vector copies, or from. 1.0* to 10 '' vector copies are suitable.
• the composition may be administered only once or may be administered two or more times to increase the immune response.
• the composition may be administered two or more times separated by one week, two weeks, three weeks, 1 month, .2 months, 3 months, 6 months, 1 year or more.
• the vaccine vector may comprise viable microorganisms prior to administration, but in some embodiments the vector may be killed prior to administration.
• the vector may be able to replicate in the subject, while in other embodiments the vector may not be capable of re licating in. the subject.
• Methods of inactivating microorganisms used as vectors are known to those of skill in the art.
• a bacterial vaccine vector may be inactivated using formalin, ethanol, heat exposure, or antibiotics. Those of skill in the art may use other methods as well.
• vaccines may encode antigens from multiple pathogenic microorganisms, viruses or tumor associated antigens.
• Administration of vaccine capable of expressing multiple antigens has the advantage of inducing immunity against two or more diseases at the same time.
• live attenuated bacteria provide a suiiabie vector for eliciting an immune response against multiple antigens from a single - 23 - pathogen, e.g.. TRAP (SEQ ID NO: 6) nd MPP from Eimeria (SEQ ID NO: 2); or against multiple antigens from different pathogens, e.g., Eimeria and Influenza or Salmonella.
• Vaccine vectors may be constructed using exogenous .
• polynucleotides encoding antigens which may be inserted into the vaccine vector at any non-essential site or 5 alternativel may be carried on a plasmid or other extra chromosomal, vehicle (e.g. a BAC or Y AC) using methods well known in the art.
• a plasmid or other extra chromosomal, vehicle e.g. a BAC or Y AC
• One suitable site for insertion of polynucleotides is within external portions of transmembrane proteins or coupled to sequences that target the exogenous polynucleotide for secretory pathways and/or allow attachment to the cell wail
• a suitable transmembrane protein, for insertion of polynucleotides is the iamB
• Exogenous polynucleotides include, but are not limited to, polynucleotides encoding antigens selected from pathogenic microorganisms or viruses and include polynucleotides that are expressed in such a way that an effective immune response generated.
• Such polynucleotides may be derived from pathogenic viruses such as influenza (e.g., M2&,
• herpesviruses e.g., the genes encoding the structural proteins of herpesviruses
• retroviruses e.g., the g l 60 envelope protein
• adenoviruses e.g., paramyxoviruses, coronaviruses and the like.
• Exogenous -polynucleotides can also be obtained from pathogenic bacteria, e.g., genes encoding bacterial proteins such as toxins, outer membrane proteins or other highly conserved proteins.
• exogenous 0 polynucleotides from, parasites, such as other Apicomplexan parasites are attractive candidates for use in a vector vaccine.
• compositions and methods disclosed herein are capable of being made, practiced, used, carried out and/or formed in 5 various ways that will be apparent to one of skill if) the art in tight of the disclosure that
• the j3 ⁇ 4?S included a sorting motif that was recognized by sortase A that anchors the j pB to the ceil surface of a sortase A expressing bacterium ⁇ Y ⁇ ,
• the vaccine sequences are placed upstream and in frame with tha hpB sequence such that when tha fhpB is anchored to sortase A on the cell wait the vaccine vector sequence will be expressed on the surface of the bacteria.
• Plasmid pNDH 10 containing the vaccine sequence, and xyl operon was transformed into Bacillus ubiiiis 1 A857 expressing sortase A [2 ], Each plasmid was transformed into I A857 by adding 0.6 pg insert plasmid into a competent ⁇ ⁇ 857 culture with 0, 1 M ethylene glycol tetraaeetic acid (EGTA). After transformation, I A857 expressing pNDH 10 were selected on LB agar containing 5 pg mL chloramphenicol to select only cells that carried antibiotic resistance conferred by the plasmid via a ai sequence that encodes chloramphenicol acetyl transferase.
• EGTA ethylene glycol tetraaeetic acid
• Vectored vaccines MPP HMGB l and TRAP MPP HMGB 1 were tested for ability to provide protection against an Eimeri maxima challenge when admi istered through the drinking water in conjunction with a modified c tosan.
• adjuvant Broiler chscks were vaccinated at 4.and .14 days of age with the respective vaccine in the drinking water at. -a dilution of 1 : 128 (5 X W cf chick) for 24h.
• All groups were weighed and challenged with 4x10* sporulated oocysts of£, maxima by oral savage.
• BW body weight
• BWG body weight gain of survivors

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Tropical Medicine & Parasitology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Zoology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Toxicology (AREA)
• Gastroenterology & Hepatology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (26)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=51354559

Family Applications (1)

Country Status (23)

Cited By (5)

Families Citing this family (5)

Citations (1)

Family Cites Families (91)

• 2014
  • 2014-02-14 US US14/768,011 patent/US9603915B2/en active Active
  • 2014-02-14 EA EA201591488A patent/EA030929B1/ru unknown
  • 2014-02-14 HU HUE14751914A patent/HUE047484T2/hu unknown
  • 2014-02-14 ES ES19194676T patent/ES2968398T3/es active Active
  • 2014-02-14 AU AU2014216246A patent/AU2014216246B2/en active Active
  • 2014-02-14 KR KR1020157024664A patent/KR102228324B1/ko active Active
  • 2014-02-14 PL PL14751914T patent/PL2956165T3/pl unknown
  • 2014-02-14 MY MYPI2018001432A patent/MY200497A/en unknown
  • 2014-02-14 CN CN202010782256.8A patent/CN111956796B/zh active Active
  • 2014-02-14 NZ NZ711019A patent/NZ711019A/en not_active IP Right Cessation
  • 2014-02-14 CA CA2900644A patent/CA2900644C/en active Active
  • 2014-02-14 CN CN201480021011.6A patent/CN105142665A/zh active Pending
  • 2014-02-14 EP EP19194676.3A patent/EP3610887B8/en active Active
  • 2014-02-14 AR ARP140100470A patent/AR094791A1/es active IP Right Grant
  • 2014-02-14 DK DK14751914T patent/DK2956165T3/da active
  • 2014-02-14 WO PCT/US2014/016359 patent/WO2014127185A1/en not_active Ceased
  • 2014-02-14 MX MX2015010555A patent/MX2015010555A/es active IP Right Grant
  • 2014-02-14 PT PT147519144T patent/PT2956165T/pt unknown
  • 2014-02-14 BR BR112015019283-1A patent/BR112015019283B1/pt active IP Right Grant
  • 2014-02-14 ES ES14751914T patent/ES2758759T3/es active Active
  • 2014-02-14 MY MYPI2015002038A patent/MY173328A/en unknown
  • 2014-02-14 JP JP2015558140A patent/JP6532407B2/ja active Active
  • 2014-02-14 SG SG11201506398SA patent/SG11201506398SA/en unknown
  • 2014-02-14 SG SG10202109925T patent/SG10202109925TA/en unknown
  • 2014-02-14 EP EP14751914.4A patent/EP2956165B1/en active Active
• 2015
  • 2015-08-05 ZA ZA2015/05638A patent/ZA201505638B/en unknown
  • 2015-08-13 PH PH12015501784A patent/PH12015501784B1/en unknown
  • 2015-08-14 CL CL2015002273A patent/CL2015002273A1/es unknown
• 2017
  • 2017-03-06 US US15/450,138 patent/US9884099B2/en active Active
• 2018
  • 2018-01-23 US US15/877,598 patent/US10328137B2/en active Active
• 2019
  • 2019-02-18 JP JP2019026326A patent/JP6874031B2/ja active Active
  • 2019-06-12 US US16/439,511 patent/US10792351B2/en active Active
• 2020
  • 2020-09-17 US US17/023,795 patent/US11364290B2/en active Active
• 2022
  • 2022-05-25 US US17/824,378 patent/US11904005B2/en active Active

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events